Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Liver Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Cyclophosphamide 13Bevacizumab 9Interleukin-2 8aldesleukin 7Paclitaxel 7fludarabine phosphate 6fludarabine 6Radiotherapy 6Bortezomib 6Thalidomide 5Gemcitabine 5Filgrastim 5veliparib 4sargramostim 4Vincristine 4Trastuzumab 4Prednisone 4Leucovorin 4Doxorubicin 4Biopsy 4vandetanib 3tariquidar 3romidepsin 3pazopanib 3montanide ISA 51 3Topotecan 3Specimen Handling 3Sorafenib 3Sirolimus 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms × carotuximab × Clear all
NCT01090765 2018-05-22

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 17 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡